Molecular Formula | C20H20FNO4 |
Molar Mass | 357.38 |
Density | 1.297 |
Boling Point | 572.7±50.0 °C(Predicted) |
Flash Point | 300.174°C |
Vapor Presure | 0mmHg at 25°C |
pKa | 14.17±0.20(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.588 |
overview | ezetimibe (Ezetimibe) is a drug jointly developed by Schering-Plough and Merck to treat hyperlipidemia. it was approved by FDA in 2002 under the trade name Zetia. Its chemical name is: 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-propionamide. Hyperlipidemia is an important risk factor for cardiovascular diseases such as atherosclerosis. Reducing the level of total cholesterol in plasma can reduce the risk of cardiovascular diseases. |
Application | (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxyvalanoyl]-4-Phenyl -1, 3-oxazepentan-2-one is used as an intermediate for the preparation of ezetimibe. Ezetimibe's current clinical drugs for the treatment of hyperlipidemia mainly include cholesterol synthesis inhibitors, phenoxy acids and bile acid chelating agents. By acting on the brush border of small intestinal cells, ezetimibe can selectively inhibit the absorption of cholesterol in the biliary tract and food without affecting the absorption of fat-soluble vitamins, triglycerides and bile acids. |
use | ezetimibe intermediate |